Albert Bourla, Pfizer CEO (Evan Vucci, AP Images)

Covid-19 roundup: Pfiz­er sub­mits EUA for Omi­cron-tar­get­ed boost­er; No­vavax EUA ex­pands to teens

The Omi­cron-tar­get­ed boost­ers are com­ing. Al­most 250 days since Omi­cron be­came the dom­i­nant vari­ant in the US, Pfiz­er and BioN­Tech on Mon­day of­fi­cial­ly an­nounced that they’ve re­quest­ed an EUA for their boost­er dose of an Omi­cron BA.4/BA.5-adapt­ed bi­va­lent vac­cine for those 12 and old­er.

The ap­pli­ca­tion’s sub­mis­sion comes as BioN­Tech said ear­li­er this month that it ex­pects to be­gin de­liv­er­ing Omi­cron-adapt­ed vac­cines as ear­ly as Oc­to­ber, sub­ject to reg­u­la­to­ry ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA